Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Atherosclerosis

Retrieve available abstracts of 261 articles:
HTML format

Single Articles

    May 2021
  1. REESKAMP LF, Nurmohamed NS, Bom MJ, Planken RN, et al
    Marked plaque regression in homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021;327:13-17.
    PubMed     Abstract available

  2. HEIDEMANN BE, Wolters FJ, Kavousi M, Gruppen EG, et al
    Adiposity and the development of dyslipidemia in APOE epsilon2 homozygous subjects: A longitudinal analysis in two population-based cohorts.
    Atherosclerosis. 2021;325:57-62.
    PubMed     Abstract available

  3. LEE JH, Lee HS, Cho AR, Lee YJ, et al
    Relationship between muscle mass index and LDL cholesterol target levels: Analysis of two studies of the Korean population.
    Atherosclerosis. 2021;325:1-7.
    PubMed     Abstract available

    April 2021
  4. BRANDTS J, Dharmayat KI, Vallejo-Vaz AJ, Azar Sharabiani MT, et al
    A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
    Atherosclerosis. 2021;325:46-56.
    PubMed     Abstract available

  5. INGOE L, Potter A, Musson S, Neely D, et al
    Improving the identification of patients with a genetic diagnosis of familial hypercholesterolaemia in primary care: A strategy to achieve the NHS long term plan.
    Atherosclerosis. 2021;325:38-45.
    PubMed     Abstract available

    Benefits and harms of LDL-cholesterol-lowering therapy in older people must be established through valid and clinically relevant evidence.
    Atherosclerosis. 2021;323:57-58.

  7. ZAFEIROPOULOS S, Farmakis I, Kartas A, Arvanitaki A, et al
    Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial.
    Atherosclerosis. 2021;323:37-43.
    PubMed     Abstract available

  8. LIMA JG, Helena C Nobrega L, Moura Bandeira FT, Pires Sousa AG, et al
    A novel GPIHBP1 mutation related to familial chylomicronemia syndrome: A series of cases.
    Atherosclerosis. 2021;322:31-38.
    PubMed     Abstract available

  9. JO SH, Han SH, Kim SH, Eckel RH, et al
    Cardiovascular effects of omega-3 fatty acids: Hope or hype?
    Atherosclerosis. 2021;322:15-23.
    PubMed     Abstract available

    March 2021
  10. BUONUOMO PS, Mastrogiorgio G, Leone G, Rana I, et al
    Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021 Mar 28. pii: S0021-9150(21)00147.

  11. ELLINS EA, Watkins S, Rees DA, Datta DBN, et al
    Acute effect of a single session of lipoprotein apheresis on central haemodynamics in patients with familial hypercholesterolaemia.
    Atherosclerosis. 2021 Mar 27. pii: S0021-9150(21)00144.

    Correspondence on: "Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features".
    Atherosclerosis. 2021 Mar 20. pii: S0021-9150(21)00125.

  13. BANACH M, Penson PE
    Lipid-lowering therapies: Better together.
    Atherosclerosis. 2021;320:86-88.

    February 2021
  14. LEREN TP, Bogsrud MP
    Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993-2020.
    Atherosclerosis. 2021;322:61-66.
    PubMed     Abstract available

  15. REESKAMP LF, Balvers M, Peter J, van de Kerkhof L, et al
    Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia.
    Atherosclerosis. 2021;321:14-20.
    PubMed     Abstract available

    January 2021
  16. VUORIO A, Raal F, Kaste M, Kovanen PT, et al
    Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment.
    Atherosclerosis. 2021;320:53-60.
    PubMed     Abstract available

  17. MARCO-BENEDI V, Laclaustra M, Bea AM, Suarez-Tembra M, et al
    Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
    Atherosclerosis. 2021;320:47-52.
    PubMed     Abstract available

  18. FUTEMA M, Ramaswami U, Tichy L, Bogsrud MP, et al
    Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Atherosclerosis. 2021;319:108-117.
    PubMed     Abstract available

  19. VALLEJO-VAZ AJ, Packard CJ, Ference BA, Santos RD, et al
    LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.
    Atherosclerosis. 2021;320:1-9.
    PubMed     Abstract available

  20. KOROSOGLOU G, Chatzizisis YS, Raggi P
    Coronary computed tomography angiography in asymptomatic patients: Still a taboo or precision medicine?
    Atherosclerosis. 2021;317:47-49.

  21. STOCK JK
    Should we treat high LDL cholesterol in 'healthy' elderly individuals?
    Atherosclerosis. 2021;317:50-51.

    December 2020
  22. RUBINO J, MacDougall DE, Sterling LR, Hanselman JC, et al
    Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
    Atherosclerosis. 2020 Dec 31. pii: S0021-9150(20)31597.
    PubMed     Abstract available

  23. SVENDSEN K, Krogh HW, Igland J, Tell GS, et al
    2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia.
    Atherosclerosis. 2020;319:28-34.
    PubMed     Abstract available

  24. COUTINHO ER, Miname MH, Rocha VZ, Bittencourt MS, et al
    Familial hypercholesterolemia and cardiovascular disease in older individuals.
    Atherosclerosis. 2020;318:32-37.
    PubMed     Abstract available

  25. SVENDSEN K, Langslet G, Krogh HW, Brinck J, et al
    Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia.
    Atherosclerosis. 2020;316:48-52.
    PubMed     Abstract available

    November 2020
  26. PEREZ DE ISLA L, Alonso R, Gomez de Diego JJ, Muniz-Grijalvo O, et al
    Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study.
    Atherosclerosis. 2020 Nov 18. pii: S0021-9150(20)31521.
    PubMed     Abstract available

  27. REESKAMP LF, Tromp TR, Huijgen R, Stroes ESG, et al
    Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation.
    Atherosclerosis. 2020;315:68-75.
    PubMed     Abstract available

    October 2020
  28. IYEN B, Qureshi N, Weng S, Roderick P, et al
    Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records.
    Atherosclerosis. 2020 Oct 31. pii: S0021-9150(20)31491.
    PubMed     Abstract available

    September 2020
  29. IQBAL Z, Ho JH, Adam S, France M, et al
    Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK.
    Atherosclerosis. 2020;313:126-136.
    PubMed     Abstract available

  30. BERTOLINI S, Calandra S, Arca M, Averna M, et al
    Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
    Atherosclerosis. 2020;312:72-78.
    PubMed     Abstract available

    August 2020
  31. RODRIGUEZ-NOVOA S, Rodriguez-Jimenez C, Alonso C, Rodriguez-Laguna L, et al
    Familial hypercholesterolemia: A single-nucleotide variant (SNV) in mosaic at the low density lipoprotein receptor (LDLR).
    Atherosclerosis. 2020;311:37-43.
    PubMed     Abstract available

  32. PEPPLINKHUIZEN S, Ibrahim S, Vink R, Groot B, et al
    Electronic health records to facilitate continuous detection of familial hypercholesterolemia.
    Atherosclerosis. 2020;310:83-87.
    PubMed     Abstract available

  33. ALJENEDIL S, Alothman L, Belanger AM, Brown L, et al
    Lomitapide for treatment of homozygous familial hypercholesterolemia: The Quebec experience.
    Atherosclerosis. 2020;310:54-63.
    PubMed     Abstract available

    July 2020
  34. RALLIDIS LS, Liberopoulos EN, Vlachopoulos C, Skoumas I, et al
    Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.
    Atherosclerosis. 2020 Jul 30. pii: S0021-9150(20)30385.

  35. FUKUMOTO K, Takemoto Y, Yoshikawa J, Norioka N, et al
    Predictors of endothelial function improvement in patients with mild hypertriglyceridemia without evidence of coronary artery disease treated with purified eicosapentaenoic acid.
    Atherosclerosis. 2020;309:27-32.
    PubMed     Abstract available

  36. GULIZIA MM, Maggioni AP, Abrignani MG, Bilato C, et al
    Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study.
    Atherosclerosis. 2020;308:32-38.
    PubMed     Abstract available

  37. PASTA A, Cremonini AL, Formisano E, Fresa R, et al
    Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
    Atherosclerosis. 2020;308:6-14.
    PubMed     Abstract available

  38. STOCK J
    Familial hypercholesterolemia: An urgent public health priority.
    Atherosclerosis. 2020 Jul 18. pii: S0021-9150(20)30351.

  39. GALLO A, Charriere S, Vimont A, Chapman MJ, et al
    SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia.
    Atherosclerosis. 2020;306:41-49.
    PubMed     Abstract available

    May 2020
  40. LAU P, Soubeyrand S, Hegele RA, Lagace TA, et al
    Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia.
    Atherosclerosis. 2020;304:39-43.
    PubMed     Abstract available

  41. STOCK JK
    Homozygous familial hypercholesterolaemia: New hope for getting patients to goal?
    Atherosclerosis. 2020 May 25. pii: S0021-9150(20)30230.

  42. ADEMI Z, Norman R, Pang J, Liew D, et al
    Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Atherosclerosis. 2020;304:1-8.
    PubMed     Abstract available

  43. TSIMIKAS S, Stroes ESG
    The dedicated "Lp(a) clinic": A concept whose time has arrived?
    Atherosclerosis. 2020;300:1-9.
    PubMed     Abstract available

    March 2020
  44. PANG J, Abraham A, Vargas-Garcia C, Bates TR, et al
    An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia.
    Atherosclerosis. 2020;298:52-57.
    PubMed     Abstract available

  45. ADINOLFI LE, Petta S, Fracanzani AL, Coppola C, et al
    Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
    Atherosclerosis. 2020;296:40-47.
    PubMed     Abstract available

  46. CHO DH, Song IS, Choi J, Gwon JG, et al
    Risk of peripheral arterial disease in patients with periodontitis: A nationwide, population-based, matched cohort study.
    Atherosclerosis. 2020;297:96-101.
    PubMed     Abstract available

    February 2020
  47. LUIRINK IK, Hutten BA, Greber-Platzer S, Kolovou GD, et al
    Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.
    Atherosclerosis. 2020;299:24-31.
    PubMed     Abstract available

  48. NORDESTGAARD BG, Langlois MR, Langsted A, Chapman MJ, et al
    Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.
    Atherosclerosis. 2020;294:46-61.
    PubMed     Abstract available

    January 2020
  49. CHIU YW, Wu CS, Chen PC, Wei YC, et al
    Risk of acute mesenteric ischemia in patients with diabetes: A population-based cohort study in Taiwan.
    Atherosclerosis. 2020;296:18-24.
    PubMed     Abstract available

  50. KOSKINEN JS, Kyto V, Juonala M, Viikari JSA, et al
    Childhood risk factors and carotid atherosclerotic plaque in adulthood: The Cardiovascular Risk in Young Finns Study.
    Atherosclerosis. 2020;293:18-25.
    PubMed     Abstract available

  51. SON DH, Lee HS, Lee YJ
    Association between serum carbohydrate antigen 19-9 levels and leukoaraiosis in middle-aged and older adults: A cross-sectional study.
    Atherosclerosis. 2020;292:188-192.
    PubMed     Abstract available

  52. MASUDA D, Miyata Y, Matsui S, Yamashita S, et al
    Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study.
    Atherosclerosis. 2020;292:163-170.
    PubMed     Abstract available

  53. MAEDA N, Funahashi T, Matsuzawa Y, Shimomura I, et al
    Adiponectin, a unique adipocyte-derived factor beyond hormones.
    Atherosclerosis. 2020;292:1-9.
    PubMed     Abstract available

    November 2019
  54. MULDER JWCM, Galema-Boers AMH, de Jong-Verweij LM, Hazelzet JA, et al
    The development and first results of a health-related outcomes set in familial hypercholesterolemia (FH) patients: Knowledge is health.
    Atherosclerosis. 2019;293:11-17.
    PubMed     Abstract available

  55. WALD DS, Bestwick JP
    Reaching detection targets in familial hypercholesterolaemia: Comparison of identification strategies.
    Atherosclerosis. 2019;293:57-61.
    PubMed     Abstract available

  56. LAMIQUIZ-MONEO I, Restrepo-Cordoba MA, Mateo-Gallego R, Bea AM, et al
    Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia.
    Atherosclerosis. 2019;292:143-151.
    PubMed     Abstract available

  57. RAMASWAMI U, Futema M, Bogsrud MP, Holven KB, et al
    Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Atherosclerosis. 2019;292:178-187.
    PubMed     Abstract available

    October 2019
  58. RAMOS R, Masana L, Comas-Cufi M, Garcia-Gil M, et al
    Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype.
    Atherosclerosis. 2019;292:42-51.
    PubMed     Abstract available

  59. CAO YX, Jin JL, Guo YL, Sun D, et al
    Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia.
    Atherosclerosis. 2019;291:27-33.
    PubMed     Abstract available

    September 2019
  60. STOCK J
    First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated.
    Atherosclerosis. 2019 Sep 28. pii: S0021-9150(19)31502.

  61. LEON-ACUNA A, Torres-Pena JD, Alcala-Diaz JF, Vals-Delgado C, et al
    Lifestyle factors modulate postprandial hypertriglyceridemia: From the CORDIOPREV study.
    Atherosclerosis. 2019;290:118-124.
    PubMed     Abstract available

  62. RAMASWAMI U, Humphries SE, Priestley-Barnham L, Green P, et al
    Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care.
    Atherosclerosis. 2019;290:1-8.
    PubMed     Abstract available

    August 2019
  63. DESJARLAIS M, Dussault S, Rivard F, Harel S, et al
    Forced expression of microRNA-146b reduces TRAF6-dependent inflammation and improves ischemia-induced neovascularization in hypercholesterolemic conditions.
    Atherosclerosis. 2019;289:73-84.
    PubMed     Abstract available

  64. HORI M, Ohta N, Takahashi A, Masuda H, et al
    Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients.
    Atherosclerosis. 2019;289:101-108.
    PubMed     Abstract available

  65. DUELL PB, Gidding SS, Andersen RL, Knickelbine T, et al
    Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.
    Atherosclerosis. 2019;289:85-93.
    PubMed     Abstract available

    July 2019
  66. ANHOLM C, Kumarathurai P, Pedersen LR, Samkani A, et al
    Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Atherosclerosis. 2019;288:60-66.
    PubMed     Abstract available

  67. LANGSTED A, Vedel-Krogh S, Kobylecki CJ, Nordestgaard BG, et al
    Reply to: "Seasonal variations of lipid profiles in a French cohort".
    Atherosclerosis. 2019;286:184-186.

  68. NADIF R, Goldberg S, Gourmelen J, Ozguler A, et al
    Seasonal variations of lipid profiles in a French cohort.
    Atherosclerosis. 2019;286:181-183.

    June 2019
  69. MASANA L, Ibarretxe D, Rodriguez-Borjabad C, Plana N, et al
    Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain.
    Atherosclerosis. 2019;287:89-92.
    PubMed     Abstract available

  70. DYRBUS K, Gasior M, Desperak P, Osadnik T, et al
    The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals.
    Atherosclerosis. 2019;288:33-41.
    PubMed     Abstract available

  71. WISLOFF T, Mundal LJ, Retterstol K, Igland J, et al
    Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects.
    Atherosclerosis. 2019;287:140-146.
    PubMed     Abstract available

    May 2019
  72. IYEN B, Qureshi N, Kai J, Akyea RK, et al
    Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study.
    Atherosclerosis. 2019;287:8-15.
    PubMed     Abstract available

  73. PEREZ DE ISLA L, Ray KK, Watts GF, Santos RD, et al
    Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2019;286:40-45.
    PubMed     Abstract available

    April 2019
  74. LUIRINK IK, Kuipers IM, Hutten BA, Planken RN, et al
    Coronary computed tomography angiography and echocardiography in children with homozygous familial hypercholesterolemia.
    Atherosclerosis. 2019;285:87-92.
    PubMed     Abstract available

  75. ALOTHMAN L, Genest J
    Chylomicrons: When you can't direct the wind, adjust the sail.
    Atherosclerosis. 2019;283:121-123.

    March 2019
  76. MIRAMONTES-GONZALEZ JP, Usategui-Martin R, Perez de Isla L, Alonso R, et al
    VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia.
    Atherosclerosis. 2019;285:17-22.
    PubMed     Abstract available

    How much further do we need to decrease LDL cholesterol levels in heterozygous familial hypercholesterolemia?
    Atherosclerosis. 2019 Mar 9. pii: S0021-9150(19)30121.

    February 2019
  78. CHEMELLO K, Martin C, Lambert G
    PCSK9 inhibition for autosomal recessive hypercholesterolemia.
    Atherosclerosis. 2019 Feb 23. pii: S0021-9150(19)30091.

  79. PEREZ-CALAHORRA S, Laclaustra M, Marco-Benedi V, Lamiquiz-Moneo I, et al
    Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia.
    Atherosclerosis. 2019 Feb 12. pii: S0021-9150(19)30081.
    PubMed     Abstract available

    January 2019
  80. RODRIGUEZ-JIMENEZ C, Gomez-Coronado D, Frias Vargas M, Cerrato F, et al
    A new variant (c.1A>G) in LDLRAP1 causing autosomal recessive hypercholesterolemia: Characterization of the defect and response to PCSK9 inhibition.
    Atherosclerosis. 2019 Jan 25. pii: S0021-9150(19)30023.
    PubMed     Abstract available

  81. YAN Y, He F, Li Z, Xu R, et al
    The important role of apolipoprotein A-II in ezetimibe driven reduction of high cholesterol diet-induced atherosclerosis.
    Atherosclerosis. 2019;280:99-108.
    PubMed     Abstract available

  82. XIAO P, Huang T, Yan Y, Zhao X, et al
    Performance of gender- and age-specific cut-points versus NCEP pediatric cutpoints in dyslipidemia screening among Chinese children.
    Atherosclerosis. 2019;280:37-44.
    PubMed     Abstract available

    December 2018
  83. WAKE M, Oh A, Onishi Y, Guelfucci F, et al
    Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan.
    Atherosclerosis. 2018;282:19-28.
    PubMed     Abstract available

  84. SANTOS RD, Watts GF
    Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH.
    Atherosclerosis. 2018 Dec 22. pii: S0021-9150(18)31544.

  85. VEDEL-KROGH S, Kobylecki CJ, Nordestgaard BG, Langsted A, et al
    The Christmas holidays are immediately followed by a period of hypercholesterolemia.
    Atherosclerosis. 2018;281:121-127.
    PubMed     Abstract available

  86. GUO J, Gao Y, Li X, He Y, et al
    Systematic prediction of familial hypercholesterolemia caused by low-density lipoprotein receptor missense mutations.
    Atherosclerosis. 2018;281:1-8.
    PubMed     Abstract available

  87. VUORIO A, Watts GF, Kovanen PT
    Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2018;281:25-30.
    PubMed     Abstract available

  88. LUNEGOVA OS, Mirrakhimov EM
    A familial hypercholesterolemia week in Kyrgyzstan: The joint scientific and practical symposium with the European Atherosclerosis Society (EAS), the International Atherosclerosis Society (IAS) and the Kyrgyz Society of Cardiology (KSC).
    Atherosclerosis. 2018 Dec 3. pii: S0021-9150(18)31511.

    November 2018
  89. SORAN H, Adam S, Durrington PN
    Reply to: "Comments on 'Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk' ".
    Atherosclerosis. 2018 Nov 28. pii: S0021-9150(18)31508.

  90. KORDONOURI O, Lange K, Boettcher I, Christoph J, et al
    New approach for detection of LDL-hypercholesterolemia in the pediatric population: The Fr1dolin-Trial in Lower Saxony, Germany.
    Atherosclerosis. 2018;280:85-91.
    PubMed     Abstract available

  91. PIRRO M, Francisci D, Bianconi V, Schiaroli E, et al
    NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial.
    Atherosclerosis. 2018;280:51-57.
    PubMed     Abstract available

  92. SHAH SR
    Comments on "Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk".
    Atherosclerosis. 2018 Nov 13. pii: S0021-9150(18)31476.

  93. HUMPHRIES SE, Cooper JA, Capps N, Durrington PN, et al
    Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register.
    Atherosclerosis. 2018 Nov 12. pii: S0021-9150(18)31469.
    PubMed     Abstract available

  94. REESKAMP LF, Kastelein JJP, Moriarty PM, Duell PB, et al
    Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2018;280:109-117.
    PubMed     Abstract available

  95. BOJANIN D, Vekic J, Milenkovic T, Vukovic R, et al
    Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
    Atherosclerosis. 2018;280:14-20.
    PubMed     Abstract available

  96. LUIJTEN J, van Greevenbroek MMJ, Schaper NC, Meex SJR, et al
    Incidence of cardiovascular disease in familial combined hyperlipidemia: A 15-year follow-up study.
    Atherosclerosis. 2018;280:1-6.
    PubMed     Abstract available

    October 2018
  97. ALHABABI D, Zayed H
    Spectrum of mutations of familial hypercholesterolemia in the 22 Arab countries.
    Atherosclerosis. 2018;279:62-72.
    PubMed     Abstract available

  98. SHEK A, Alieva R, Kurbanov R, Hoshimov S, et al
    Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle.
    Atherosclerosis. 2018;277:524-529.
    PubMed     Abstract available

  99. MEHTA R, Martagon AJ, Galan Ramirez GA, Gonzalez Retana G, et al
    The development of the Mexican Familial Hypercholesterolemia (FH) National Registry.
    Atherosclerosis. 2018;277:517-523.
    PubMed     Abstract available

  100. AZRAII AB, Ramli AS, Ismail Z, Abdul-Razak S, et al
    Knowledge, awareness and practice regarding familial hypercholesterolaemia among primary care physicians in Malaysia: The importance of professional training.
    Atherosclerosis. 2018;277:508-516.
    PubMed     Abstract available

  101. BOTHA TC, Pilcher GJ, Wolmarans K, Blom DJ, et al
    Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies.
    Atherosclerosis. 2018;277:502-507.
    PubMed     Abstract available

  102. HAGGER MS, Hardcastle SJ, Hu M, Kwok S, et al
    Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:493-501.
    PubMed     Abstract available

  103. RAAL FJ, Hovingh GK, Catapano AL
    Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Atherosclerosis. 2018;277:483-492.
    PubMed     Abstract available

  104. AFANASIEVA OI, Ezhov MV, Razova OA, Afanasieva MI, et al
    Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Atherosclerosis. 2018;277:477-482.
    PubMed     Abstract available

  105. PANG J, David Marais A, Blom DJ, Brice BC, et al
    Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice.
    Atherosclerosis. 2018;277:470-476.
    PubMed     Abstract available

  106. SOUTO AC, Miname MH, Fukushima J, Jannes CE, et al
    Health related quality of life in individuals at high risk for familial hypercholesterolemia undergoing genetic cascade screening in Brazil.
    Atherosclerosis. 2018;277:464-469.
    PubMed     Abstract available

  107. FUTEMA M, Bourbon M, Williams M, Humphries SE, et al
    Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia.
    Atherosclerosis. 2018;277:457-463.
    PubMed     Abstract available

  108. ALVES AC, Benito-Vicente A, Medeiros AM, Reeves K, et al
    Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia.
    Atherosclerosis. 2018;277:448-456.
    PubMed     Abstract available

  109. HSIUNG YC, Lin PC, Chen CS, Tung YC, et al
    Identification of a novel LDLR disease-causing variant using capture-based next-generation sequencing screening of familial hypercholesterolemia patients in Taiwan.
    Atherosclerosis. 2018;277:440-447.
    PubMed     Abstract available

  110. LOPEZ G, Bernal LM, Gelvez N, Gomez LF, et al
    Mutational analysis of the LDLR gene in a cohort of Colombian families with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:434-439.
    PubMed     Abstract available

  111. ALNOURI F, Athar M, Al-Allaf FA, Abduljaleel Z, et al
    Novel combined variants of LDLR and LDLRAP1 genes causing severe familial hypercholesterolemia.
    Atherosclerosis. 2018;277:425-433.
    PubMed     Abstract available

  112. BRUNHAM LR, Ruel I, Khoury E, Hegele RA, et al
    Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.
    Atherosclerosis. 2018;277:419-424.
    PubMed     Abstract available

  113. PETRULIONIENE Z, Gargalskaite U, Kutkiene S, Staigyte J, et al
    Establishing a national screening programme for familial hypercholesterolaemia in Lithuania.
    Atherosclerosis. 2018;277:407-412.
    PubMed     Abstract available

  114. BRETT T, Qureshi N, Gidding S, Watts GF, et al
    Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part.
    Atherosclerosis. 2018;277:399-406.
    PubMed     Abstract available

  115. TRUONG TH, Kim NT, Nguyen MNT, Pang J, et al
    Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families.
    Atherosclerosis. 2018;277:392-398.
    PubMed     Abstract available

  116. GROSELJ U, Kovac J, Sustar U, Mlinaric M, et al
    Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review.
    Atherosclerosis. 2018;277:383-391.
    PubMed     Abstract available

  117. PAYNE J, Williams S, Maxwell D, Pariente MT, et al
    Familial hypercholesterolaemia patient support groups and advocacy: A multinational perspective.
    Atherosclerosis. 2018;277:377-382.
    PubMed     Abstract available

  118. DESCAMPS OS, Van Caenegem O, Hermans MP, Balligand JL, et al
    A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy).
    Atherosclerosis. 2018;277:369-376.
    PubMed     Abstract available

  119. HARADA-SHIBA M, Ako J, Arai H, Hirayama A, et al
    Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study.
    Atherosclerosis. 2018;277:362-368.
    PubMed     Abstract available

  120. VRABLIK M, Raslova K, Vohnout B, Blaha V, et al
    Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Atherosclerosis. 2018;277:355-361.
    PubMed     Abstract available

  121. LATKOVSKIS G, Saripo V, Gilis D, Nesterovics G, et al
    Latvian registry of familial hypercholesterolemia: The first report of three-year results.
    Atherosclerosis. 2018;277:347-354.
    PubMed     Abstract available

  122. KAYIKCIOGLU M, Tokgozoglu L, Dogan V, Ceyhan C, et al
    What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?
    Atherosclerosis. 2018;277:341-346.
    PubMed     Abstract available

  123. BELIARD S, Boccara F, Cariou B, Carrie A, et al
    High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Atherosclerosis. 2018;277:334-340.
    PubMed     Abstract available

  124. VAN DELDEN XM, Huijgen R, Wolmarans KH, Brice BC, et al
    LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    Atherosclerosis. 2018;277:327-333.
    PubMed     Abstract available

  125. VOHNOUT B, Fabryova L, Klabnik A, Kadurova M, et al
    Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice.
    Atherosclerosis. 2018;277:323-326.
    PubMed     Abstract available

  126. SCHMIDT N, Dressel A, Grammer TB, Gouni-Berthold I, et al
    Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
    Atherosclerosis. 2018;277:314-322.
    PubMed     Abstract available

  127. RIZOS CV, Elisaf MS, Skoumas I, Tziomalos K, et al
    Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
    Atherosclerosis. 2018;277:308-313.
    PubMed     Abstract available

  128. IBARRETXE D, Rodriguez-Borjabad C, Feliu A, Bilbao JA, et al
    Detecting familial hypercholesterolemia earlier in life by actively searching for affected children:The DECOPIN project.
    Atherosclerosis. 2018;278:210-216.
    PubMed     Abstract available

  129. DUMITRESCU A, Mosteoru S, Vinereanu D, Dan GA, et al
    Preliminary data of familial hypercholesterolemia (FH) patients in Romania.
    Atherosclerosis. 2018;277:304-307.
    PubMed     Abstract available

  130. LALIC K, Rajkovic N, Popovic L, Lukac SS, et al
    The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia.
    Atherosclerosis. 2018;277:298-303.
    PubMed     Abstract available

    Epidemiology of familial hypercholesterolaemia: Community and clinical.
    Atherosclerosis. 2018;277:289-297.
    PubMed     Abstract available

  132. MISEREZ AR, Martin FJ, Spirk D
    DIAgnosis and Management Of familial hypercholesterolemia in a Nationwide Design (DIAMOND-FH): Prevalence in Switzerland, clinical characteristics and the diagnostic value of clinical scores.
    Atherosclerosis. 2018;277:282-288.
    PubMed     Abstract available

  133. POJSKIC L, Pojskic B
    Familial hypercholesterolemia screening program in Bosnia and Herzegovina and cardiovascular morbidity.
    Atherosclerosis. 2018;277:278-281.
    PubMed     Abstract available

  134. HARADA PH, Miname MH, Bensenor IM, Santos RD, et al
    Familial hypercholesterolemia prevalence in an admixed racial society: Sex and race matter. The ELSA-Brasil.
    Atherosclerosis. 2018;277:273-277.
    PubMed     Abstract available

  135. KUTKIENE S, Petrulioniene Z, Laucevicius A, Cerkauskiene R, et al
    Lipid profile evaluation and severe hypercholesterolaemia screening in the middle-aged population according to nationwide primary prevention programme in Lithuania.
    Atherosclerosis. 2018;277:267-272.
    PubMed     Abstract available

  136. PARAGH G, Harangi M, Karanyi Z, Daroczy B, et al
    Identifying patients with familial hypercholesterolemia using data mining methods in the Northern Great Plain region of Hungary.
    Atherosclerosis. 2018;277:262-266.
    PubMed     Abstract available

  137. CORRAL P, Geller AS, Polisecki EY, Lopez GI, et al
    Unusual genetic variants associated with hypercholesterolemia in Argentina.
    Atherosclerosis. 2018;277:256-261.
    PubMed     Abstract available

  138. VALLEJO-VAZ AJ, De Marco M, Stevens CAT, Akram A, et al
    Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    Atherosclerosis. 2018;277:234-255.
    PubMed     Abstract available

  139. RAY KK, Watts GF
    Improving the global care of familial hypercholesterolaemia: Starting the ball rolling.
    Atherosclerosis. 2018;277:230-233.

    September 2018
  140. JUNG KJ, Koh H, Choi Y, Lee SJ, et al
    Familial hypercholesterolemia and atherosclerotic cardiovascular mortality among Korean adults with low levels of serum cholesterol.
    Atherosclerosis. 2018;278:103-109.
    PubMed     Abstract available

  141. FARNIER M, Hovingh GK, Langslet G, Dufour R, et al
    Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program.
    Atherosclerosis. 2018 Sep 1. pii: S0021-9150(18)31345.
    PubMed     Abstract available

    August 2018
  142. CHUNG CM, Lin MS, Liu CH, Lee TH, et al
    Discontinuing or continuing statin following intracerebral hemorrhage from the view of a national cohort study.
    Atherosclerosis. 2018;278:15-22.
    PubMed     Abstract available

  143. SORAN H, Adam S, Durrington PN
    Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
    Atherosclerosis. 2018;278:135-142.
    PubMed     Abstract available

  144. BELIARD S, Gallo A, Duchene E, Carrie A, et al
    Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort.
    Atherosclerosis. 2018;277:66-71.
    PubMed     Abstract available

    July 2018
  145. MARTIN SS
    Calculating LDL cholesterol in familial combined hyperlipidemia: Out with the old, in with the new?
    Atherosclerosis. 2018 Jul 27. pii: S0021-9150(18)31241.

  146. CAO YX, Liu HH, Sun D, Jin JL, et al
    The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:7-14.
    PubMed     Abstract available

    June 2018
  147. ADEMI Z, Martin AC
    Universal screening of children for familial hypercholesterolaemia: Value for money?
    Atherosclerosis. 2018 Jun 22. pii: S0021-9150(18)31186.

  148. MEHTA R, Reyes-Rodriguez E, Yaxmehen Bello-Chavolla O, Guerrero-Diaz AC, et al
    Performance of LDL-C calculated with Martin's formula compared to the Friedewald equation in familial combined hyperlipidemia.
    Atherosclerosis. 2018 Jun 21. pii: S0021-9150(18)31180.
    PubMed     Abstract available

  149. BALLANTYNE CM, Banach M, Mancini GBJ, Lepor NE, et al
    Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Atherosclerosis. 2018 Jun 12. pii: S0021-9150(18)30309.
    PubMed     Abstract available

  150. MCKAY AJ, Hogan H, Humphries SE, Marks D, et al
    Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
    Atherosclerosis. 2018 Jun 4. pii: S0021-9150(18)30290.
    PubMed     Abstract available

    May 2018
  151. MULLER HH
    Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis: Corrections of the report on the randomized MICA-study.
    Atherosclerosis. 2018 May 30. pii: S0021-9150(18)30260.

  152. SUNG KC, Lee MY, Kim YH, Huh JH, et al
    Obesity and incidence of diabetes: Effect of absence of metabolic syndrome, insulin resistance, inflammation and fatty liver.
    Atherosclerosis. 2018;275:50-57.
    PubMed     Abstract available

  153. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Reply to: "Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis: Corrections of the report on the randomized MICA-study".
    Atherosclerosis. 2018 May 22. pii: S0021-9150(18)30261.

  154. CROSLAND P, Maconachie R, Buckner S, McGuire H, et al
    Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales.
    Atherosclerosis. 2018;275:80-87.
    PubMed     Abstract available

  155. HUMPHRIES SE, Cooper JA, Seed M, Capps N, et al
    Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register.
    Atherosclerosis. 2018;274:41-46.
    PubMed     Abstract available

    April 2018
  156. WENG S, Kai J, Tranter J, Leonardi-Bee J, et al
    Improving identification and management of familial hypercholesterolaemia in primary care: Pre- and post-intervention study.
    Atherosclerosis. 2018;274:54-60.
    PubMed     Abstract available

  157. MACEDONI M, Hovnik T, Plesnik E, Kotnik P, et al
    Metabolic control, ApoE genotypes, and dyslipidemia in children, adolescents and young adults with type 1 diabetes.
    Atherosclerosis. 2018;273:53-58.
    PubMed     Abstract available

    March 2018
  158. WAKE M, Onishi Y, Guelfucci F, Oh A, et al
    Treatment patterns in hyperlipidaemia patients based on administrative claim databases in Japan.
    Atherosclerosis. 2018;272:145-152.
    PubMed     Abstract available

    February 2018
  159. VITVEROVA B, Blazickova K, Najmanova I, Vicen M, et al
    Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta.
    Atherosclerosis. 2018;271:15-25.
    PubMed     Abstract available

  160. FOGACCI F, Cicero AFG
    Gene targeting for chylomicronemia syndrome: The brave new world.
    Atherosclerosis. 2018;269:254-255.

    January 2018
  161. PELCZARSKA A, Jakubczyk M, Jakubiak-Lasocka J, Banach M, et al
    The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
    Atherosclerosis. 2018;270:132-138.
    PubMed     Abstract available

  162. RODRIGUEZ-BORJABAD C, Ibarretxe D, Girona J, Ferre R, et al
    Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia.
    Atherosclerosis. 2018;270:117-122.
    PubMed     Abstract available

  163. KAYIKCIOGLU M, Tokgozoglu L, Yilmaz M, Kaynar L, et al
    A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry).
    Atherosclerosis. 2018;270:42-48.
    PubMed     Abstract available

  164. DROUIN-CHARTIER JP, Tremblay AJ, Bergeron J, Lamarche B, et al
    High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.
    Atherosclerosis. 2018;270:26-32.
    PubMed     Abstract available

    December 2017
  165. PEK SLT, Dissanayake S, Fong JCW, Lin MX, et al
    Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
    Atherosclerosis. 2017;269:106-116.
    PubMed     Abstract available

  166. SANCHEZ-HERNANDEZ RM, Prieto-Matos P, Civeira F, Lafuente EE, et al
    Autosomal recessive hypercholesterolemia in Spain.
    Atherosclerosis. 2017;269:1-5.
    PubMed     Abstract available

    October 2017
  167. HOEKE G, Wang Y, van Dam AD, Mol IM, et al
    Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
    Atherosclerosis. 2017;267:116-126.
    PubMed     Abstract available

  168. AMROCK SM, Duell PB, Knickelbine T, Martin SS, et al
    Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry.
    Atherosclerosis. 2017;267:19-26.
    PubMed     Abstract available

    September 2017
  169. HOVLAND A, Mundal LJ, Igland J, Veierod MB, et al
    Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2017;266:69-73.
    PubMed     Abstract available

  170. CHRISTENSEN JJ, Ulven SM, Retterstol K, Narverud I, et al
    Comprehensive lipid and metabolite profiling of children with and without familial hypercholesterolemia: A cross-sectional study.
    Atherosclerosis. 2017;266:48-57.
    PubMed     Abstract available

  171. KAWASHIRI MA, Nohara A, Higashikata T, Tada H, et al
    Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Atherosclerosis. 2017;265:225-230.
    PubMed     Abstract available

    August 2017
  172. GITT AK, Lautsch D, Ferrieres J, De Ferrari GM, et al
    Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
    Atherosclerosis. 2017;266:158-166.
    PubMed     Abstract available

  173. SCHMIDT N, Schmidt B, Dressel A, Gergei I, et al
    Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) study.
    Atherosclerosis. 2017;266:24-30.
    PubMed     Abstract available

    July 2017
  174. NIKKOLA E, Ko A, Alvarez M, Cantor RM, et al
    Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family.
    Atherosclerosis. 2017;264:58-66.
    PubMed     Abstract available

  175. YANG ZH, Gordon SM, Sviridov D, Wang S, et al
    Dietary supplementation with long-chain monounsaturated fatty acid isomers decreases atherosclerosis and alters lipoprotein proteomes in LDLr(-/-) mice.
    Atherosclerosis. 2017;262:31-38.
    PubMed     Abstract available

  176. CHO I, O Hartaigh B, Gransar H, Valenti V, et al
    Prognostic implications of coronary artery calcium in the absence of coronary artery luminal narrowing.
    Atherosclerosis. 2017;262:185-190.
    PubMed     Abstract available

  177. STEINHAGEN-THIESSEN E, Stroes E, Soran H, Johnson C, et al
    The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency.
    Atherosclerosis. 2017;262:146-153.
    PubMed     Abstract available

    June 2017
  178. SILVA PRS, Jannes CE, Oliveira TGM, Miname MH, et al
    Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil.
    Atherosclerosis. 2017;263:257-262.
    PubMed     Abstract available

  179. SANTOS RD, Miname MH
    Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype: What do genetic defects tell us and what are the clinical implications?
    Atherosclerosis. 2017 Jun 12. pii: S0021-9150(17)30254.

  180. VONGPROMEK R, Bos S, Ten Kate GR, Bujo H, et al
    Soluble LR11 associates with aortic root calcification in asymptomatic treated male patients with familial hypercholesterolemia.
    Atherosclerosis. 2017 Jun 9. pii: S0021-9150(17)30268.
    PubMed     Abstract available

  181. BEA AM, Perez-Calahorra S, Marco-Benedi V, Lamiquiz-Moneo I, et al
    Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia.
    Atherosclerosis. 2017;263:92-96.
    PubMed     Abstract available

  182. TERAMOTO T, Daida H, Ikewaki K, Arai H, et al
    Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.
    Atherosclerosis. 2017;261:69-77.
    PubMed     Abstract available

  183. ARAI H, Yamashita S, Yokote K, Araki E, et al
    Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipida
    Atherosclerosis. 2017;261:144-152.
    PubMed     Abstract available

    May 2017
  184. HAGENSEN MK, Mortensen MB, Kjolby M, Stillits NL, et al
    Type 1 diabetes increases retention of low-density lipoprotein in the atherosclerosis-prone area of the murine aorta.
    Atherosclerosis. 2017;263:7-14.
    PubMed     Abstract available

  185. SHARIFI M, Higginson E, Bos S, Gallivan A, et al
    Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.
    Atherosclerosis. 2017 May 13. pii: S0021-9150(17)30218.
    PubMed     Abstract available

  186. MASANA L, Plana N, Perez-Calahorra S, Ibarretxe D, et al
    How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Atherosclerosis. 2017;262:107-112.
    PubMed     Abstract available

  187. BUONUOMO PS, Iughetti L, Pisciotta L, Rabacchi C, et al
    Timely diagnosis of sitosterolemia by next generation sequencing in two children with severe hypercholesterolemia.
    Atherosclerosis. 2017;262:71-77.
    PubMed     Abstract available

  188. OTHMAN RA, Myrie SB, Mymin D, Roullet JB, et al
    Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia.
    Atherosclerosis. 2017;260:27-33.
    PubMed     Abstract available

    April 2017
  189. MANGILI LC, Miname MH, Silva PRS, Bittencourt MS, et al
    Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study.
    Atherosclerosis. 2017 Apr 30. pii: S0021-9150(17)30189.
    PubMed     Abstract available

  190. BOURBON M, Alves AC, Alonso R, Mata N, et al
    Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry.
    Atherosclerosis. 2017;262:8-13.
    PubMed     Abstract available

  191. HIGUCHI S, Kabeya Y, Kato K
    Visceral-to-subcutaneous fat ratio is independently related to small and large cerebrovascular lesions even in healthy subjects.
    Atherosclerosis. 2017;259:41-45.
    PubMed     Abstract available

    March 2017
  192. LI S, Wu NQ, Zhu CG, Zhang Y, et al
    Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.
    Atherosclerosis. 2017;260:67-74.
    PubMed     Abstract available

  193. FUTEMA M, Cooper JA, Charakida M, Boustred C, et al
    Screening for familial hypercholesterolaemia in childhood: Avon Longitudinal Study of Parents and Children (ALSPAC).
    Atherosclerosis. 2017;260:47-55.
    PubMed     Abstract available

    February 2017
  194. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Atherosclerosis. 2017;259:20-25.
    PubMed     Abstract available

  195. JANUS ED
    Homozygous familial hypercholesterolaemia - Early recognition and early treatment improve outcomes.
    Atherosclerosis. 2017 Feb 16. pii: S0021-9150(17)30060.

  196. XIANG R, Fan LL, Lin MJ, Li JJ, et al
    The genetic spectrum of familial hypercholesterolemia in the central south region of China.
    Atherosclerosis. 2017;258:84-88.
    PubMed     Abstract available

  197. LADWIG KH, Baumert J, Marten-Mittag B, Lukaschek K, et al
    Room for depressed and exhausted mood as a risk predictor for all-cause and cardiovascular mortality beyond the contribution of the classical somatic risk factors in men.
    Atherosclerosis. 2017;257:224-231.
    PubMed     Abstract available

  198. DI COSTANZO A, D'Erasmo L, Polimeni L, Baratta F, et al
    Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage.
    Atherosclerosis. 2017;257:232-239.
    PubMed     Abstract available

    January 2017
  199. WIDHALM K, Benke IM, Fritz M, Geiger H, et al
    Homozygous familial hypercholesterolemia: Summarized case reports.
    Atherosclerosis. 2017;257:86-89.
    PubMed     Abstract available

  200. BRUCKERT E, Kalmykova O, Bittar R, Carreau V, et al
    Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
    Atherosclerosis. 2017;257:130-137.
    PubMed     Abstract available

  201. BOS S, Duvekot MH, Ten Kate GR, Verhoeven AJ, et al
    Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study.
    Atherosclerosis. 2017;256:62-66.
    PubMed     Abstract available

  202. NONIN S, Iwata S, Sugioka K, Fujita S, et al
    Plaque surface irregularity and calcification length within carotid plaque predict secondary events in patients with coronary artery disease.
    Atherosclerosis. 2017;256:29-34.
    PubMed     Abstract available

  203. ANDREOZZI F, Mannino GC, Perticone M, Perticone F, et al
    Elevated 1-h post-load plasma glucose levels in subjects with normal glucose tolerance are associated with a pro-atherogenic lipid profile.
    Atherosclerosis. 2017;256:15-20.
    PubMed     Abstract available

    December 2016
  204. DURST R, Ibe UK, Shpitzen S, Schurr D, et al
    Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Atherosclerosis. 2016;257:55-63.
    PubMed     Abstract available

  205. PANES O, Gonzalez C, Hidalgo P, Valderas JP, et al
    Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin.
    Atherosclerosis. 2016;257:164-171.
    PubMed     Abstract available

  206. CHRISTENSEN JJ, Osnes LT, Halvorsen B, Retterstol K, et al
    Altered leukocyte distribution under hypercholesterolemia: A cross-sectional study in children with familial hypercholesterolemia.
    Atherosclerosis. 2016;256:67-74.
    PubMed     Abstract available

    November 2016
  207. FRANCE M, Rees A, Datta D, Thompson G, et al
    HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
    Atherosclerosis. 2016 Nov 5. pii: S0021-9150(16)31420.
    PubMed     Abstract available

    October 2016
  208. SETIA N, Saxena R, Arora A, Verma IC, et al
    Spectrum of mutations in homozygous familial hypercholesterolemia in India, with four novel mutations.
    Atherosclerosis. 2016;255:31-36.
    PubMed     Abstract available

  209. DANCER M, Caussy C, Di Filippo M, Moulin P, et al
    Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3'UTR variant SstI.
    Atherosclerosis. 2016;255:6-10.
    PubMed     Abstract available

  210. CASULA M, Scotti L, Tragni E, Merlino L, et al
    Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2016;254:172-178.
    PubMed     Abstract available

  211. OGURA M, Makino H, Kamiya C, Yoshimatsu J, et al
    Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion.
    Atherosclerosis. 2016;254:179-183.
    PubMed     Abstract available

    September 2016
  212. KOSTNER K
    Coronary calcification in familial hypercholesterolemia: Not all about LDL.
    Atherosclerosis. 2016 Sep 28. pii: S0021-9150(16)31377.

  213. MARTIN R, Latten M, Hart P, Murray H, et al
    Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations.
    Atherosclerosis. 2016;254:8-13.
    PubMed     Abstract available

  214. MANGILI LC, Mangili OC, Bittencourt MS, Miname MH, et al
    Epicardial fat is associated with severity of subclinical coronary atherosclerosis in familial hypercholesterolemia.
    Atherosclerosis. 2016;254:73-77.
    PubMed     Abstract available

  215. ARCA M
    Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Atherosclerosis. 2016 Sep 2. pii: S0021-9150(16)31315.
    PubMed     Abstract available

    August 2016
  216. ALONSO R, Mata P, Muniz O, Fuentes-Jimenez F, et al
    PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
    Atherosclerosis. 2016 Aug 27. pii: S0021-9150(16)31306.
    PubMed     Abstract available

  217. GRENKOWITZ T, Kassner U, Wuhle-Demuth M, Salewsky B, et al
    Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Atherosclerosis. 2016;253:88-93.
    PubMed     Abstract available

    July 2016
  218. WATTS GF, Pang J, Chan DC, Brunt JN, et al
    Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin.
    Atherosclerosis. 2016;252:82-87.
    PubMed     Abstract available

    Knowledge equals health; why all healthcare professionals should know about familial hypercholesterolemia.
    Atherosclerosis. 2016 Jul 30. pii: S0021-9150(16)31229.

  220. TORVIK K, Narverud I, Ottestad I, Svilaas A, et al
    Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia.
    Atherosclerosis. 2016;252:21-27.
    PubMed     Abstract available

  221. SCHOFIELD J, Kwok S, France M, Capps N, et al
    Knowledge gaps in the management of familial hypercholesterolaemia. A UK based survey.
    Atherosclerosis. 2016 Jul 10. pii: S0021-9150(16)30308.
    PubMed     Abstract available

  222. SJOUKE B, Defesche JC, de Randamie JS, Wiegman A, et al
    Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2016;251:263-265.
    PubMed     Abstract available

    May 2016
  223. SILVA PR, Jannes CE, Marsiglia JD, Krieger JE, et al
    Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia.
    Atherosclerosis. 2016;250:144-150.
    PubMed     Abstract available

  224. NARDIN M, Verdoia M, Schaffer A, Barbieri L, et al
    Vitamin D status, diabetes mellitus and coronary artery disease in patients undergoing coronary angiography.
    Atherosclerosis. 2016;250:114-121.
    PubMed     Abstract available

  225. BANERJEE Y, Santos RD, Al-Rasadi K, Rizzo M, et al
    Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
    Atherosclerosis. 2016;248:62-75.
    PubMed     Abstract available

  226. ZHOU T, Ding JW, Wang XA, Zheng XX, et al
    Long noncoding RNAs and atherosclerosis.
    Atherosclerosis. 2016;248:51-61.
    PubMed     Abstract available

  227. PAN L, Yang Z, Wu Y, Yin RX, et al
    The prevalence, awareness, treatment and control of dyslipidemia among adults in China.
    Atherosclerosis. 2016;248:2-9.
    PubMed     Abstract available

    April 2016
  228. KRAUZOVA E, Kracmerova J, Rossmeislova L, Malisova L, et al
    Acute hyperlipidemia initiates proinflammatory and proatherogenic changes in circulation and adipose tissue in obese women.
    Atherosclerosis. 2016;250:151-157.
    PubMed     Abstract available

  229. HUANG Y, Xu M, Xie L, Wang T, et al
    Obesity and peripheral arterial disease: A Mendelian Randomization analysis.
    Atherosclerosis. 2016;247:218-24.
    PubMed     Abstract available

  230. KOLODZIEJCZAK M, Navarese EP
    Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature.
    Atherosclerosis. 2016;247:189-92.
    PubMed     Abstract available

    March 2016
  231. MICKIEWICZ A, Chmara M, Futema M, Fijalkowski M, et al
    Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland.
    Atherosclerosis. 2016;249:52-58.
    PubMed     Abstract available

  232. ARAI H, Teramoto T, Daida H, Ikewaki K, et al
    Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2016 Mar 25. pii: S0021-9150(16)30092.
    PubMed     Abstract available

  233. RALLIDIS LS, Triantafyllis AS, Tsirebolos G, Katsaras D, et al
    Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins.
    Atherosclerosis. 2016;249:17-21.
    PubMed     Abstract available

  234. RAAL FJ, Sjouke B, Hovingh GK, Isaac BF, et al
    Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study.
    Atherosclerosis. 2016 Mar 11. pii: S0021-9150(16)30084.
    PubMed     Abstract available

  235. STEFFENSEN LB, Conover CA, Bjorklund MM, Ledet T, et al
    Stanniocalcin-2 overexpression reduces atherosclerosis in hypercholesterolemic mice.
    Atherosclerosis. 2016;248:36-43.
    PubMed     Abstract available

  236. ROTLLAN N, Price N, Pati P, Goedeke L, et al
    microRNAs in lipoprotein metabolism and cardiometabolic disorders.
    Atherosclerosis. 2016;246:352-60.
    PubMed     Abstract available

  237. EL TAHLAWI M, Sakrana A, Elmurr A, Gouda M, et al
    The relation between coronary tortuosity and calcium score in patients with chronic stable angina and normal coronaries by CT angiography.
    Atherosclerosis. 2016;246:334-7.
    PubMed     Abstract available

  238. CAUSSY C, Charriere S, Meirhaeghe A, Dallongeville J, et al
    Multiple microRNA regulation of lipoprotein lipase gene abolished by 3'UTR polymorphisms in a triglyceride-lowering haplotype harboring p.Ser474Ter.
    Atherosclerosis. 2016;246:280-6.
    PubMed     Abstract available

  239. PEDERSEN LR, Olsen RH, Anholm C, Walzem RL, et al
    Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary, overweight population with stable coronary artery disease: A randomized trial.
    Atherosclerosis. 2016;246:221-8.
    PubMed     Abstract available

  240. ESCATE R, Padro T, Badimon L
    LDL accelerates monocyte to macrophage differentiation: Effects on adhesion and anoikis.
    Atherosclerosis. 2016;246:177-86.
    PubMed     Abstract available

  241. POKHAREL Y, Steinberg L, Chan W, Akeroyd JM, et al
    Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline.
    Atherosclerosis. 2016;246:115-20.
    PubMed     Abstract available

  242. SCHWEITZER M, Makhoul S, Paliouras M, Beitel LK, et al
    Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe.
    Atherosclerosis. 2016;246:78-86.
    PubMed     Abstract available

    February 2016
  243. AMOR AJ, Catalan M, Perez A, Herreras Z, et al
    Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis.
    Atherosclerosis. 2016;247:161-169.
    PubMed     Abstract available

  244. SANNA C, Stephenne X, Revencu N, Smets F, et al
    Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.
    Atherosclerosis. 2016;247:97-104.
    PubMed     Abstract available

  245. HERNANDEZ-MIJARES A, Banuls C, Rovira-Llopis S, Diaz-Morales N, et al
    Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia.
    Atherosclerosis. 2016;247:40-47.
    PubMed     Abstract available

    January 2016
  246. BAILA-RUEDA L, Perez-Ruiz MR, Jarauta E, Tejedor MT, et al
    Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes.
    Atherosclerosis. 2016;246:202-207.
    PubMed     Abstract available

  247. ZHENG L, Wu T, Zeng C, Li X, et al
    SAP deficiency mitigated atherosclerotic lesions in ApoE(-/-) mice.
    Atherosclerosis. 2016;244:179-87.
    PubMed     Abstract available

  248. FARNIER M, Jones P, Severance R, Averna M, et al
    Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Atherosclerosis. 2016;244:138-46.
    PubMed     Abstract available

    December 2015
  249. RASMUSSEN KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R, et al
    Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population.
    Atherosclerosis. 2015;246:63-70.
    PubMed     Abstract available

  250. BESSELING J, Huijgen R, Martin SS, Hutten BA, et al
    Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia.
    Atherosclerosis. 2015;246:1-6.
    PubMed     Abstract available

  251. NIIMI M, Yang D, Kitajima S, Ning B, et al
    ApoE knockout rabbits: A novel model for the study of human hyperlipidemia.
    Atherosclerosis. 2015;245:187-193.
    PubMed     Abstract available

    October 2015
  252. BASU A, Jenkins AJ, Zhang Y, Stoner JA, et al
    Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes.
    Atherosclerosis. 2015;244:93-100.
    PubMed     Abstract available

  253. SCHOFIELD J, Bhatnagar D
    The impact of gestational hypercholesterolaemia on origins of disease.
    Atherosclerosis. 2015 Oct 22. pii: S0021-9150(15)30160.

  254. RATHOUSKA J, Jezkova K, Nemeckova I, Nachtigal P, et al
    Soluble endoglin, hypercholesterolemia and endothelial dysfunction.
    Atherosclerosis. 2015;243:383-388.
    PubMed     Abstract available

    September 2015
  255. THOMPSON GR, Seed M, Naoumova RP, Neuwirth C, et al
    Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes.
    Atherosclerosis. 2015;243:328-333.
    PubMed     Abstract available

  256. VALLEJO-VAZ AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, et al
    Familial hypercholesterolaemia: A global call to arms.
    Atherosclerosis. 2015;243:257-259.

  257. IRAWATI D, Mamo JC, Soares MJ, Slivkoff-Clark KM, et al
    Hypertriglyceridemic subjects exhibit an accumulation of small dense chylomicron particles in the fasting state.
    Atherosclerosis. 2015;243:236-241.
    PubMed     Abstract available

  258. NARVERUD I, van Lennep JR, Christensen JJ, Versmissen J, et al
    Maternal inheritance does not predict cholesterol levels in children with familial hypercholesterolemia.
    Atherosclerosis. 2015;243:155-160.
    PubMed     Abstract available

  259. SHIN DG, Han SM, Kim DI, Rhee MY, et al
    Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis.
    Atherosclerosis. 2015;243:53-58.
    PubMed     Abstract available

  260. BARKAS F, Elisaf M, Milionis H
    Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.
    Atherosclerosis. 2015;243:60-64.
    PubMed     Abstract available

    August 2015
  261. YU HH, Chen PC, Yang YH, Wang LC, et al
    Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.
    Atherosclerosis. 2015;243:11-18.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.